Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration
about
Potencies of human immunodeficiency virus protease inhibitors in vitro against Plasmodium falciparum and in vivo against murine malariaThe effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects.Maraviroc: in vitro assessment of drug-drug interaction potentialPlasma amprenavir pharmacokinetics and tolerability following administration of 1,400 milligrams of fosamprenavir once daily in combination with either 100 or 200 milligrams of ritonavir in healthy volunteersOral contraception does not alter single dose saquinavir pharmacokinetics in womenThe effects of ritonavir and lopinavir/ritonavir on the pharmacokinetics of a novel CCR5 antagonist, aplaviroc, in healthy subjects.P-glycoprotein related drug interactions: clinical importance and a consideration of disease states.Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS).Drug interactions: a primer for the gastroenterologistMembrane Assays to Characterize Interaction of Drugs with ABCB1.Saquinavir Loaded Acetalated Dextran Microconfetti - a Long Acting Protease Inhibitor Injectable.Unexpected Hepatotoxicity of Rifampin and Saquinavir/Ritonavir in Healthy Male Volunteers.Adherence to antiretroviral therapy and its impact on clinical outcome in HIV-infected patients.Dyslipidemia due to retroviral protease inhibitors.Pharmacokinetic and tolerability profile of twice-daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers.Lack of interaction between enfuvirtide and ritonavir or ritonavir-boosted saquinavir in HIV-1-infected patients.The effects of once-daily saquinavir/minidose ritonavir on the pharmacokinetics of methadone.Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients.Quantification of human hepatocyte cytochrome P450 enzymes and transporters induced by HIV protease inhibitors using newly validated LC-MS/MS cocktail assays and RT-PCR.Clarification of P-glycoprotein inhibition-related drug-drug interaction risks based on a literature search of the clinical information.Dyslipidemia in an Asian population after treatment for two years with protease inhibitor-containing regimens.British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2005).Efficacy, Safety and Pharmacokinetics of Once-Daily Saquinavir Soft-Gelatin Capsule/Ritonavir in Antiretroviral-Naive, HIV-Infected Patients.
P2860
Q24538763-42519D62-F4EC-4098-8563-9A101C5A35ABQ30692710-C61F7AA6-8D4E-4385-A5A7-DD67741C2115Q34594626-B5C62FC5-6DA0-4D93-A1B5-0413FFF88E75Q35636050-212094E0-11B1-475C-8F89-B8DF98412E6FQ35825971-E1F42CFA-7F65-4CC3-AE93-2E62A4693D4EQ35827755-9E2FC50F-B157-42CD-9539-99A302FB3167Q37732337-930488FF-54D5-43CE-A2B7-80EDC032BD2EQ37988960-A3E2D3FD-EC73-4154-9662-8BE984F728B3Q38039067-382BD86B-79D5-4D55-BB81-C73DD06F6330Q38880731-539CECA2-B790-4CFE-93F4-698BC36390C7Q39787241-C8DAEEEE-4846-40E8-AABF-C8D5030A4226Q42618217-068AD009-5497-4F3F-861D-20F97DC84E82Q43260037-86011BCA-F7C1-45AB-A485-CAD721F1CD3BQ43943674-4AF461FD-63F3-457F-A833-BE79F4A1419EQ44408007-86AE02ED-1503-4450-ACA2-30A978E4209AQ44543678-B4059E75-3651-4B17-A67A-ED900D7A09F6Q44770188-B1D0CC44-5728-4B2C-909D-B1CE348E8467Q46571243-591EA110-6BE6-419F-B4EF-8E7C17325209Q47909730-35C9878F-8887-476F-AAB9-DD4DA6480EC9Q50668713-925FD912-2395-4810-8DCD-43B2CB152AA4Q51476626-A236D62E-C9D9-40B9-9836-553F9D3F69C5Q53851252-F32DC73F-57F8-4D55-9F89-C83720A97BAFQ55698438-6DE83BBC-5A3E-490E-9370-602738EBF639
P2860
Saquinavir and ritonavir pharmacokinetics following combined ritonavir and saquinavir (soft gelatin capsules) administration
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Saquinavir and ritonavir pharm ...... latin capsules) administration
@ast
Saquinavir and ritonavir pharm ...... latin capsules) administration
@en
Saquinavir and ritonavir pharm ...... latin capsules) administration
@nl
type
label
Saquinavir and ritonavir pharm ...... latin capsules) administration
@ast
Saquinavir and ritonavir pharm ...... latin capsules) administration
@en
Saquinavir and ritonavir pharm ...... latin capsules) administration
@nl
prefLabel
Saquinavir and ritonavir pharm ...... latin capsules) administration
@ast
Saquinavir and ritonavir pharm ...... latin capsules) administration
@en
Saquinavir and ritonavir pharm ...... latin capsules) administration
@nl
P2093
P2860
P1476
Saquinavir and ritonavir pharm ...... latin capsules) administration
@en
P2093
P2860
P304
P356
10.1046/J.0306-5251.2001.01452.X
P407
P577
2001-09-01T00:00:00Z